Lycobetaine acts as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells
2001
Lycobetaine and Its Effects on Tumor Growth
Sample size: 21
publication
Evidence: moderate
Author Information
Author(s): Barthelmes H U, Niederberger E, Roth T, Schulte K, Tang W C, Boege F, Fiebig H-H, Eisenbrand G, Marko D
Primary Institution: University of Kaiserslautern
Hypothesis
Lycobetaine acts as a selective topoisomerase IIβ poison that inhibits the growth of human tumor cells.
Conclusion
Lycobetaine significantly inhibits the growth of human tumor cells and acts as a specific topoisomerase IIβ poison.
Supporting Evidence
- Lycobetaine inhibited the growth of 21 human tumor xenografts with a mean IC50 of 0.8 μM.
- Human leukemia cell lines showed a mean IC50 of 1.3 μM when treated with lycobetaine.
- Treatment with lycobetaine resulted in a marked tumor growth delay in mice with human gastric tumor xenografts.
Takeaway
Lycobetaine is a substance that can slow down the growth of certain cancer cells.
Methodology
The study used a clonogenic assay on human tumor xenografts and treated athymic nude mice with lycobetaine.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website